Head and neck cancer
EORTC-1206-HNCG (Principal Investigator: dr. J. Buter)
A randomized phase II study to evaluate the efficacy and safety of chemotherpay (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs).
Checkmate 714 (CA209-714) (Principal Investigator: dr. J. Buter)
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
MK3475-412 (Principal Investigator: dr. J. Buter)
A Randomized Phase III study of pembrolizumab given concomitantly to chemoradiation and as maintenance therapy versus chemoradiation alone in patients with locally advanced squamous cell carcinoma of the head and neck.